# Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

Source: https://onco.cc/trials/nct07612280/  
OnCo record `nct07612280` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JBI-802 in myeloproliferative neoplasms and chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Jubilant Therapeutics Inc., now recruiting.

## Summary

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis is a phase 1/2 interventional study registered as NCT07612280 by Jubilant Therapeutics Inc., with 30 participants planned, started 2024-10-21 and due to reach its primary completion in 2028-06-15. Interventions recorded: JBI-802.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07612280
- Phase: 1/2
- Setting: Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
- Sponsor: Jubilant Therapeutics Inc.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07612280: https://clinicaltrials.gov/study/NCT07612280

## Connected records

- cancers: [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [JBI-802](https://onco.cc/drugs/jbi-802/)

---
JSON: https://onco.cc/api/v1/entities/nct07612280.json